Humog 150 – human menopausal gonadotropin (HMG 150IU), produced from the urine of women in the postmenopausal period. The drug contains FSH and LH in a 1: 1 ratio.
It has follicle-stimulating and gonadotropic effects. Increases the concentration of sex hormones in plasma.
In women, it causes an increase in the concentration of estrogen in the blood and stimulates the growth of the ovaries, the maturation of follicles and ovulation in them, and causes the proliferation of the endometrium. In men, it stimulates spermatogenesis (due to the activation of the synthesis of proteins that bind androgens in the seminiferous tubules and Sertoli cells), activates the production of testosterone.
Efficacy is mainly due to the action of FSH.
The maximum concentration of FSH in the blood plasma is reached after 6-24 h after i / m administration, after which the concentration of FSH in the blood gradually decreases. The half-life is 4-12 hours.
INDICATIONS FOR USE
female infertility associated with impaired follicular maturation, against the background of hypogonadotropic ovarian failure;
stimulation of superovulation (growth of many follicles to conduct assisted reproductive techniques that promote the onset of conception) in combination with human chorionic gonadotropin (hCG);
male infertility associated with impaired spermatogenesis on the background of hypogonadotropic hypogonadism in combination with hCG.